Liposomal drug delivery systems for the treatment of leishmaniasis

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorTUON, Felipe Francisco
dc.contributor.authorDANTAS, Leticia Ramos
dc.contributor.authorSOUZA, Regina Maia de
dc.contributor.authorRIBEIRO, Victoria Stadler Tasca
dc.contributor.authorAMATO, Valdir Sabbaga
dc.date.accessioned2022-12-21T13:23:00Z
dc.date.available2022-12-21T13:23:00Z
dc.date.issued2022
dc.description.abstractHuman leishmaniasis is a vector-borne, neglected infectious disease that is widely distributed in America, Africa, Europe, and Asia. Current therapy is based on old and toxic drugs, including antimonials, aminoglycosides, and amphotericin. As a neglected disease, investment in the development of new therapeutic molecules is scarce. Considering these aspects, the optimization of treatment through novel delivery systems for current therapeutic agents is an attractive alternative. The encapsulation into liposomes of drugs used in treating leishmaniasis increases the concentration of these molecules in macrophages, which may not only increase the chance of cure but also expand their therapeutic spectrum to include resistant Leishmania, as well as reducing toxicity since the drug is less exposed to healthy cells. The classical example is the liposomal formulation of amphotericin B, a well-established therapeutic option that uses liposomes to decrease the progression of renal failure in patients. However, loading other leishmanicidal drugs into liposomes, such as pentavalent antimonials, presents an opportunity for innovative and cheaper therapeutic options for the treatment of human leishmaniasis. This review aims to discuss liposomes as a drug delivery system for leishmanicidal drugs.eng
dc.description.indexMEDLINEeng
dc.identifier.citationPARASITOLOGY RESEARCH, v.121, n.11, p.3073-3082, 2022
dc.identifier.doi10.1007/s00436-022-07659-5
dc.identifier.eissn1432-1955
dc.identifier.issn0932-0113
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/50536
dc.language.isoeng
dc.publisherSPRINGEReng
dc.relation.ispartofParasitology Research
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright SPRINGEReng
dc.subjectLeishmaniasiseng
dc.subjectLiposomeseng
dc.subjectDrug delivery systemeng
dc.subjectParasiteseng
dc.subject.otherworld cutaneous leishmaniasiseng
dc.subject.othermucosal leishmaniasiseng
dc.subject.otherantileishmanial activityeng
dc.subject.othermeglumine antimoniateeng
dc.subject.otherin-vitroeng
dc.subject.othervisceral leishmaniasiseng
dc.subject.otheramphotericin-beng
dc.subject.othersodium stibogluconateeng
dc.subject.othertrifluralin analogseng
dc.subject.othertopical treatmenteng
dc.subject.wosParasitologyeng
dc.titleLiposomal drug delivery systems for the treatment of leishmaniasiseng
dc.typearticleeng
dc.type.categoryrevieweng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.author.externalTUON, Felipe Francisco:Pontificia Univ Catolica Parana, Sch Med, Lab Emerging Infect Dis, BR-80215901 Curitiba, Parana, Brazil
hcfmusp.author.externalDANTAS, Leticia Ramos:Pontificia Univ Catolica Parana, Sch Med, Lab Emerging Infect Dis, BR-80215901 Curitiba, Parana, Brazil
hcfmusp.author.externalRIBEIRO, Victoria Stadler Tasca:Pontificia Univ Catolica Parana, Sch Med, Lab Emerging Infect Dis, BR-80215901 Curitiba, Parana, Brazil
hcfmusp.citation.scopus10
hcfmusp.contributor.author-fmusphcREGINA MAIA DE SOUZA
hcfmusp.contributor.author-fmusphcVALDIR SABBAGA AMATO
hcfmusp.description.beginpage3073
hcfmusp.description.endpage3082
hcfmusp.description.issue11
hcfmusp.description.volume121
hcfmusp.origemWOS
hcfmusp.origem.pubmed36112211
hcfmusp.origem.scopus2-s2.0-85138166540
hcfmusp.origem.wosWOS:000854405200001
hcfmusp.publisher.cityNEW YORKeng
hcfmusp.publisher.countryUNITED STATESeng
hcfmusp.relation.referenceAltamura F, 2022, DRUG DEVELOP RES, V83, P225, DOI 10.1002/ddr.21664eng
hcfmusp.relation.referenceAlvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671eng
hcfmusp.relation.referenceAmato VS, 2009, J EUR ACAD DERMATOL, V23, P1026, DOI 10.1111/j.1468-3083.2009.03238.xeng
hcfmusp.relation.referenceAmato VS, 2011, AM J TROP MED HYG, V85, P818, DOI 10.4269/ajtmh.2011.11-0287eng
hcfmusp.relation.referenceAmato VS, 2008, ACTA TROP, V105, P1, DOI 10.1016/j.actatropica.2007.08.003eng
hcfmusp.relation.referenceAmato VS, 2007, AM J TROP MED HYG, V77, P266, DOI 10.4269/ajtmh.2007.77.266eng
hcfmusp.relation.referenceAmato VS, 2007, CLIN INFECT DIS, V44, P311, DOI 10.1086/510494eng
hcfmusp.relation.referenceAmato VS, 2009, INT J DERMATOL, V48, P1091, DOI 10.1111/j.1365-4632.2009.04099.xeng
hcfmusp.relation.referenceAmer Eglal I, 2016, J Parasit Dis, V40, P475, DOI 10.1007/s12639-014-0529-0eng
hcfmusp.relation.referenceAzevedo EG, 2014, EXPERT OPIN DRUG DEL, V11, P1551, DOI 10.1517/17425247.2014.932347eng
hcfmusp.relation.referenceBacha HA, 2011, T ROY SOC TROP MED H, V105, P173, DOI 10.1016/j.trstmh.2010.11.010eng
hcfmusp.relation.referenceTuon FF, 2009, INT J DERMATOL, V48, P201, DOI 10.1111/j.1365-4632.2009.03982.xeng
hcfmusp.relation.referenceSilva JRV, 2020, EXP PARASITOL, V217, DOI 10.1016/j.exppara.2020.107934eng
hcfmusp.relation.referenceValladares JE, 1997, AM J TROP MED HYG, V57, P403, DOI 10.4269/ajtmh.1997.57.403eng
hcfmusp.relation.referenceVarma DM, 2021, ACS BIOMATER SCI ENG, V7, P1725, DOI 10.1021/acsbiomaterials.0c01132eng
hcfmusp.relation.referenceVENNERSTROM JL, 1990, ANTIMICROB AGENTS CH, V34, P918, DOI 10.1128/AAC.34.5.918eng
hcfmusp.relation.referenceTavares GDV, 2018, BASIC CLIN PHARMACOL, V123, P236, DOI 10.1111/bcpt.12990eng
hcfmusp.relation.referenceWant MY, 2017, INT J NANOMED, V12, P2189, DOI 10.2147/IJN.S106548eng
hcfmusp.relation.referenceWolf B, 1998, DRUG DEV IND PHARM, V24, P1007, DOI 10.3109/03639049809089944eng
hcfmusp.relation.referenceWyllie S, 2004, J BIOL CHEM, V279, P39925, DOI 10.1074/jbc.M405635200eng
hcfmusp.relation.referenceYANG DM, 1993, PARASITOLOGY, V106, P7, DOI 10.1017/S0031182000074758eng
hcfmusp.relation.referenceYesilova Y, 2016, J DERMATOL TREAT, V27, P83, DOI 10.3109/09546634.2015.1054778eng
hcfmusp.relation.referenceZhang RY, 2010, PARASITOL RES, V107, P475, DOI 10.1007/s00436-010-1906-yeng
hcfmusp.relation.referenceBasu MK, 2004, CURR MOL MED, V4, P681, DOI 10.2174/1566524043360186eng
hcfmusp.relation.referenceBelo VS, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002982eng
hcfmusp.relation.referenceBERMAN JD, 1985, ANTIMICROB AGENTS CH, V27, P916, DOI 10.1128/AAC.27.6.916eng
hcfmusp.relation.referenceBurza S, 2018, LANCET, V392, P951, DOI 10.1016/S0140-6736(18)31204-2eng
hcfmusp.relation.referenceCalvo A, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12090858eng
hcfmusp.relation.referenceCamargo RA, 2010, AM J TROP MED HYG, V83, P515, DOI 10.4269/ajtmh.2010.10-0081eng
hcfmusp.relation.referenceCury TAC, 2015, J MICROENCAPSUL, V32, P467, DOI 10.3109/02652048.2015.1046518eng
hcfmusp.relation.referenceCarneiro G, 2010, J LIPOSOME RES, V20, P16, DOI 10.3109/08982100903015025eng
hcfmusp.relation.referenceCarvalheiro M, 2015, EUR J PHARM BIOPHARM, V93, P346, DOI 10.1016/j.ejpb.2015.04.018eng
hcfmusp.relation.referenceCauchetier E, 2000, INT J PARASITOL, V30, P777, DOI 10.1016/S0020-7519(00)00053-9eng
hcfmusp.relation.referenceCHAN MMY, 1990, SCIENCE, V249, P924, DOI 10.1126/science.2392684eng
hcfmusp.relation.referenceChan-Bacab MJ, 2009, J ANTIMICROB CHEMOTH, V63, P1292, DOI 10.1093/jac/dkp117eng
hcfmusp.relation.referenceCogo J, 2018, BIOORGAN MED CHEM, V26, P4065, DOI 10.1016/j.bmc.2018.06.033eng
hcfmusp.relation.referenceCraft N, 2014, CLIN VACCINE IMMUNOL, V21, P1314, DOI 10.1128/CVI.00338-14eng
hcfmusp.relation.referenceCroft SL, 2006, CLIN MICROBIOL REV, V19, P111, DOI 10.1128/CMR.19.1.111-126.2006eng
hcfmusp.relation.referenceCROFT SL, 1992, J ANTIMICROB CHEMOTH, V30, P827, DOI 10.1093/jac/30.6.827eng
hcfmusp.relation.referenceDar MJ, 2020, EUR J PHARM SCI, V145, DOI 10.1016/j.ejps.2020.105256eng
hcfmusp.relation.referenceDar MJ, 2018, DRUG DELIV, V25, P1595, DOI 10.1080/10717544.2018.1494222eng
hcfmusp.relation.referencede Almeida L, 2017, J BIOMED NANOTECHNOL, V13, P117, DOI 10.1166/jbn.2017.2349eng
hcfmusp.relation.referencede Barros NB, 2016, INT IMMUNOPHARMACOL, V36, P225, DOI 10.1016/j.intimp.2016.04.025eng
hcfmusp.relation.referencede Camargo RA, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003001eng
hcfmusp.relation.referenceEmami T, 2018, ARTIF CELL NANOMED B, V46, P324, DOI 10.1080/21691401.2018.1457042eng
hcfmusp.relation.referenceBafghi AF, 2021, PREP BIOCHEM BIOTECH, V51, P990, DOI 10.1080/10826068.2021.1885045eng
hcfmusp.relation.referenceFerreira FM, 2014, PARASITOL RES, V113, P533, DOI 10.1007/s00436-013-3685-8eng
hcfmusp.relation.referenceFerreira LS, 2004, DRUG DEV IND PHARM, V30, P289, DOI 10.1081/DDC-120030423eng
hcfmusp.relation.referenceFuentes-Nava G, 2021, REV SOC BRAS MED TRO, V54, DOI 10.1590/0037-8682-0305-2020eng
hcfmusp.relation.referenceGardner DM, 2010, PHOTOCHEM PHOTOBIOL, V86, P645, DOI 10.1111/j.1751-1097.2010.00705.xeng
hcfmusp.relation.referenceGebreyohannes EA, 2018, INFECT DIS POVERTY, V7, DOI 10.1186/s40249-018-0491-7eng
hcfmusp.relation.referenceGharbi M, 2020, TRANSBOUND EMERG DIS, V67, P8, DOI 10.1111/tbed.13312eng
hcfmusp.relation.referenceGrover R, 1997, Rev Environ Contam Toxicol, V153, P1eng
hcfmusp.relation.referenceHussain Z, 2019, DRUG DELIV TRANSL RE, V9, P721, DOI 10.1007/s13346-019-00631-4eng
hcfmusp.relation.referenceKarimkhani C, 2017, LANCET INFECT DIS, V17, P264, DOI 10.1016/S1473-3099(16)30217-1eng
hcfmusp.relation.referenceKarimkhani C, 2016, LANCET INFECT DIS, V16, P584, DOI 10.1016/S1473-3099(16)00003-7eng
hcfmusp.relation.referenceKhalil EAG, 2006, SAUDI MED J, V27, P90eng
hcfmusp.relation.referenceLala S, 2004, J DRUG TARGET, V12, P165, DOI 10.1080/10611860410001712696eng
hcfmusp.relation.referenceLasic DD, 1998, TRENDS BIOTECHNOL, V16, P307, DOI 10.1016/S0167-7799(98)01220-7eng
hcfmusp.relation.referenceLopes RM, 2016, NANOMEDICINE-UK, V11, P153, DOI 10.2217/nnm.15.190eng
hcfmusp.relation.referenceMantyla A, 2004, J MED CHEM, V47, P188, DOI 10.1021/jm030868aeng
hcfmusp.relation.referenceMarti-Marti I, 2021, ENFERM INFEC MICR CL, V39, P108, DOI 10.1016/j.eimc.2020.04.005eng
hcfmusp.relation.referenceMatlashewski G, 2011, LANCET INFECT DIS, V11, P322, DOI 10.1016/S1473-3099(10)70320-0eng
hcfmusp.relation.referenceMCHARDY N, 1985, RES VET SCI, V39, P29, DOI 10.1016/S0034-5288(18)31765-Xeng
hcfmusp.relation.referenceMedda S, 1999, J ANTIMICROB CHEMOTH, V44, P791, DOI 10.1093/jac/44.6.791eng
hcfmusp.relation.referenceMedkour H, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008947eng
hcfmusp.relation.referenceMesquita JT, 2013, ACTA TROP, V128, P666, DOI 10.1016/j.actatropica.2013.09.018eng
hcfmusp.relation.referenceMinodier P, 2008, PEDIATR INFECT DIS J, V27, P80, DOI 10.1097/INF.0b013e3181506683eng
hcfmusp.relation.referenceMonteiro LM, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9781603eng
hcfmusp.relation.referenceMoosavian SA, 2019, EXP PARASITOL, V200, P30, DOI 10.1016/j.exppara.2019.03.004eng
hcfmusp.relation.referenceNEAL RA, 1988, ANN TROP MED PARASIT, V82, P453, DOI 10.1080/00034983.1988.11812275eng
hcfmusp.relation.referenceOliveira MC, 2005, REV SOC BRAS MED TRO, V38, P258, DOI 10.1590/S0037-86822005000300011eng
hcfmusp.relation.referenceOwais M., 2005, Current Drug Delivery, V2, P311, DOI 10.2174/156720105774370177eng
hcfmusp.relation.referencePal S, 2004, ANTIMICROB AGENTS CH, V48, P3591, DOI 10.1128/AAC.48.9.3591-3593.2004eng
hcfmusp.relation.referencePassos SR, 2014, INT J ANTIMICROB AG, V44, P463, DOI 10.1016/j.ijantimicag.2014.07.011eng
hcfmusp.relation.referencePeine KJ, 2014, J ANTIMICROB CHEMOTH, V69, P168, DOI 10.1093/jac/dkt320eng
hcfmusp.relation.referencePinto EG, 2020, CHEM-BIOL INTERACT, V332, DOI 10.1016/j.cbi.2020.109296eng
hcfmusp.relation.referencePokharel P, 2021, J TROP MED-US, V2021, DOI 10.1155/2021/8629039eng
hcfmusp.relation.referenceProulx ME, 2001, ANTIMICROB AGENTS CH, V45, P2623, DOI 10.1128/AAC.45.9.2623-2627.2001eng
hcfmusp.relation.referenceRaay B, 1999, INDIAN J BIOCHEM BIO, V36, P248eng
hcfmusp.relation.referenceRajabi O, 2016, DERMATOL THER, V29, P358, DOI 10.1111/dth.12357eng
hcfmusp.relation.referenceRamos GS, 2021, BIOMED PHARMACOTHER, V134, DOI 10.1016/j.biopha.2020.111120eng
hcfmusp.relation.referenceReimao JQ, 2012, EXP PARASITOL, V130, P195, DOI 10.1016/j.exppara.2012.01.010eng
hcfmusp.relation.referenceReimao JQ, 2010, PARASITOL RES, V106, P1465, DOI 10.1007/s00436-010-1826-xeng
hcfmusp.relation.referenceReis PG, 2013, J AOAC INT, V96, P771, DOI 10.5740/jaoacint.10-263eng
hcfmusp.relation.referenceRocio C, 2014, T ROY SOC TROP MED H, V108, P176, DOI 10.1093/trstmh/tru011eng
hcfmusp.relation.referenceRomanelli MM, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00353eng
hcfmusp.relation.referenceRoychoudhury J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017376eng
hcfmusp.relation.referenceSanna V, 2014, INT J NANOMED, V9, P467, DOI 10.2147/IJN.S36654eng
hcfmusp.relation.referenceSantos CCP, 2020, ANTIMICROB AGENTS CH, V64eng
hcfmusp.relation.referenceSantos J, 2000, An Med Interna, V17, P562eng
hcfmusp.relation.referenceSchettini DA, 2006, INT J PHARMACEUT, V315, P140, DOI 10.1016/j.ijpharm.2006.01.048eng
hcfmusp.relation.referenceSchwendener RA, 2007, ADV EXP MED BIOL, V620, P117eng
hcfmusp.relation.referenceSen R, 2010, INT J ANTIMICROB AG, V36, P43, DOI 10.1016/j.ijantimicag.2010.03.008eng
hcfmusp.relation.referenceSmith L, 2018, MOL PHARMACEUT, V15, P2570, DOI 10.1021/acs.molpharmaceut.8b00097eng
hcfmusp.relation.referenceReis LES, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.00962-17eng
hcfmusp.relation.referenceSundar S, 2010, J GLOB INFECT DIS, V2, P159, DOI 10.4103/0974-777X.62886eng
hcfmusp.relation.referenceTavares GSV, 2019, PARASITOL INT, V68, P63, DOI 10.1016/j.parint.2018.10.005eng
hcfmusp.relation.referenceTaylor VM, 2011, ANTIMICROB AGENTS CH, V55, P4755, DOI 10.1128/AAC.00671-11eng
hcfmusp.relation.referenceTeixeira AC, 2008, REV INST MED TROP SP, V50, P157, DOI 10.1590/S0036-46652008000300005eng
hcfmusp.relation.referenceTempone AG, 2010, INT J ANTIMICROB AG, V36, P159, DOI 10.1016/j.ijantimicag.2010.04.006eng
hcfmusp.relation.referenceBorborema SET, 2018, BIOMED PHARMACOTHER, V103, P1609, DOI 10.1016/j.biopha.2018.05.004eng
hcfmusp.relation.referenceBorborema SET, 2011, INT J ANTIMICROB AG, V38, P341, DOI 10.1016/j.ijantimicag.2011.05.012eng
hcfmusp.relation.referenceTuon FF, 2008, REV INST MED TROP SP, V50, P313, DOI 10.1590/S0036-46652008000500013eng
hcfmusp.relation.referenceTuon FF, 2008, INT J DERMATOL, V47, P109, DOI 10.1111/j.1365-4632.2008.03417.xeng
hcfmusp.relation.referenceTuon FF, 2007, CLIN INFECT DIS, V44, P1525, DOI 10.1086/517848eng
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication9615afce-f662-48cc-88b2-911fb8585bab
relation.isAuthorOfPublication8605618c-a3c4-44f8-bda7-e86858789a79
relation.isAuthorOfPublication.latestForDiscovery9615afce-f662-48cc-88b2-911fb8585bab
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_TUON_Liposomal_drug_delivery_systems_for_the_treatment_of_2022.PDF
Tamanho:
979.59 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - LIM/46